ALK and lung cancer: To further explore the molecular mechanism of poor outcomes in patients with ALK fusion lung cancer who did not receive targeted therapy, we have identified significantly mutated genes (SMGs) and pathways on 5 ALK-positive lung cancer samples and the corresponding pericarcinous (normal) tissues using whole exome sequencing (WES) analysis.